enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
enGene Holdings (Nasdaq: ENGN) has granted inducement equity awards to seven newly-hired employees effective January 29, 2025. The awards consist of non-qualified stock options to purchase a total of 262,900 common shares at an exercise price of $7.39 per share, matching the closing price on the grant date.
The stock options have a 10-year term and will vest over four years, with 25% vesting after one year and the remaining vesting monthly over three years, contingent on continued employment. These grants were approved by the Company's independent Compensation Committee as employment inducements under NASDAQ Rule 5635(c)(4).
enGene is currently conducting a pivotal study of its non-viral lead investigational product detalimogene voraplasmid for high-risk, BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.
enGene Holdings (Nasdaq: ENGN) ha concesso premi azionari di indennità a sette nuovi dipendenti a partire dal 29 gennaio 2025. I premi consistono in opzioni su azioni non qualificate per l'acquisto di un totale di 262.900 azioni ordinarie a un prezzo di esercizio di $7,39 per azione, corrispondente al prezzo di chiusura della data di concessione.
Le opzioni azionarie hanno un termine di 10 anni e matureranno nel corso di quattro anni, con il 25% che matura dopo un anno e il restante che matura mensilmente per tre anni, soggetto a un'occupazione continuativa. Questi premi sono stati approvati dal Comitato per la Compensazione indipendente dell'Azienda come indennità all'assunzione ai sensi della Regola 5635(c)(4) di NASDAQ.
enGene sta attualmente conducendo uno studio fondamentale del suo prodotto investigativo non virale di punta, il detalimogene voraplasmid, per il cancro della vescica non muscolo invasivo ad alto rischio e non responsivo al BCG con carcinoma in situ.
enGene Holdings (Nasdaq: ENGN) ha otorgado premios de acciones por motivo de contratación a siete nuevos empleados a partir del 29 de enero de 2025. Los premios consisten en opciones de compra de acciones no calificadas para adquirir un total de 262,900 acciones ordinarias a un precio de ejercicio de $7.39 por acción, coincidiendo con el precio de cierre en la fecha de concesión.
Las opciones de acciones tienen un plazo de 10 años y se consolidarán durante cuatro años, con un 25% consolidándose después de un año y el resto consolidándose mensualmente durante tres años, dependiendo de la continuidad del empleo. Estos premios fueron aprobados por el Comité de Compensación independiente de la Compañía como incentivos de empleo bajo la Regla 5635(c)(4) de NASDAQ.
enGene está actualmente llevando a cabo un estudio pivotal de su producto investigacional no viral, detalimogene voraplasmid, para el cáncer de vejiga no invasivo muscular de alto riesgo que no responde al BCG con carcinoma in situ.
enGene Holdings (Nasdaq: ENGN)은 2025년 1월 29일자로 신규 채용된 7명의 직원에게 유인 주식 보상을 부여했습니다. 이 보상은 총 262,900주를 구매할 수 있는 비자격 주식 옵션으로 구성되어 있으며, 행사 가격은 $7.39 per share로, 부여일의 종가와 일치합니다.
주식 옵션은 10년 기간을 가지며 4년에 걸쳐 배분되며, 1년 후 25%가 배분하고 나머지는 3년에 걸쳐 매월 배분되며 지속적인 고용 조건이 붙습니다. 이 보상은 NASDAQ 규칙 5635(c)(4)에 따라 고용 유인을 위한 것으로 회사의 독립 보상 위원회에 의해 승인되었습니다.
enGene은 현재 고위험, BCG 비반응성 비근육 침습성 방광암과 함께 제자리 암이 있는 비바이러스 주요 연구 제품인 detalimogene voraplasmid의 중요한 연구를 진행 중입니다.
enGene Holdings (Nasdaq: ENGN) a accordé des attributions d'actions incitatives à sept nouveaux employés à compter du 29 janvier 2025. Les attributions consistent en des options d'achat d'actions non qualifiées pour l'achat d'un total de 262 900 actions ordinaires à un prix d'exercice de $7,39 par action, correspondant au prix de clôture à la date de l'attribution.
Les options d'achat d'actions ont une durée de 10 ans et seront acquises sur quatre ans, avec 25 % acquises après un an et le reste acquis mensuellement pendant trois ans, sous réserve d'un emploi continu. Ces attributions ont été approuvées par le Comité de Rémunération indépendant de la Société en tant qu'incitations à l'emploi conformément à la règle 5635(c)(4) de NASDAQ.
enGene mène actuellement une étude clé sur son produit investigational phare non viral, le detalimogene voraplasmid, pour le cancer de la vessie non musculaire invasif à haut risque et non réactif au BCG avec carcinome in situ.
enGene Holdings (Nasdaq: ENGN) hat sieben neu eingestellten Mitarbeitern ab dem 29. Januar 2025 Anreizaktienoptionen gewährt. Die Auszeichnungen bestehen aus nicht qualifizierten Aktienoptionen zum Kauf von insgesamt 262.900 Stammaktien zu einem Ausübungspreis von $7,39 pro Aktie, was dem Schlusskurs am Gewährungstag entspricht.
Die Aktienoptionen haben eine Laufzeit von 10 Jahren und werden über vier Jahre fällig, wobei 25 % nach einem Jahr fällig werden und die verbleibenden monatlich über drei Jahre fällig werden, abhängig von der fortgesetzten Beschäftigung. Diese Ausgaben wurden vom unabhängigen Vergabekomitee des Unternehmens als Anreize für die Beschäftigung gemäß NASDAQ-Regel 5635(c)(4) genehmigt.
enGene führt derzeit eine entscheidende Studie zu seinem nicht-viralen Hauptforschungsprodukt detalimogene voraplasmid für ein hohes Risiko, BCG-resistentes, nicht-muskulär-invasives Blasenkarzinom mit Carcinoma in situ durch.
- Stock options granted align management incentives with shareholder interests through long-term vesting schedule
- Company maintains ability to attract talent through competitive compensation packages
- Potential dilution of existing shareholders from 262,900 new stock options
The inducement awards consist of a non-qualified stock options to purchase an aggregate 262,900 of the Company's common shares. The options each have an exercise price of
The stock options were granted by the Company's independent Compensation Committee of the Board of Directors as an inducement material to each new employee entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). While the stock options were granted outside of the Company’s Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan (Plan), each option will have terms and conditions consistent with those set forth under the Plan.
About enGene
enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. For more information, visit enGene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250131922136/en/
For media contact:
908-577-4531
mediainquiries@grcomms.com
For investor contact: investors@engene.com
Source: enGene Holdings Inc.
FAQ
How many stock options did ENGN grant in its January 2025 inducement awards?
What is the exercise price for ENGN's January 2025 inducement stock options?
What is the vesting schedule for ENGN's January 2025 inducement stock options?
What clinical trial is ENGN currently conducting with detalimogene voraplasmid?
